HHealthcare Read More New peptide drugs on the horizon with PepLib–Lilly collabFebruary 10, 2026 New global partnership aims to turn PepLib’s peptide tech into therapies that could reshape treatment and longevity. Think…
HHealthcare Read More What’s the Better Long-Term Investment?February 10, 2026 Novo Nordisk (NYSE: NVO) and Eli Lilly (NYSE: LLY) are rivals in the GLP-1 drug market and are…
HHealthcare Read More The most controversial Super Bowl ad of 2025 is back for moreFebruary 7, 2026 Super Bowl Sunday is the holy grail of advertising thanks to its massive viewership, with an average of…
MMedication Read More Hims and Hers Health’s compounded Wegovy pill offering fuels market jittersFebruary 5, 2026 Feb 5 (Reuters) – Hims & Hers said it would begin offering compounded versions of Novo Nordisk’s Wegovy…
HHealthcare Read More Eli Lilly Soared by 39% in 2025, but Here’s Another Healthcare Stock to Buy in 2026February 4, 2026 Eli Lilly’s (NYSE: LLY) share price jumped 39% in 2025, driven by investors eager to benefit from the…
HHealthcare Read More My Top AI Healthcare Stock to Buy and Hold for 20 YearsJanuary 27, 2026 Eli Lilly has made several moves to boost its artificial intelligence (AI) capacity. It could help complement its…
MMedication Read More How Will Ozempic and Wegovy Sales Aid NVO’s Upcoming Q4 Results?January 26, 2026 Novo Nordisk NVO is a dominant player in the cardiometabolic space, mainly due to the encouraging uptake of its…
HHealthcare Read More Eli Lilly Soared by 39% in 2025, but Here’s Another Healthcare Stock to Buy in 2026January 25, 2026 Eli Lilly (NYSE: LLY) delivered a gain worthy of a technology growth stock last year. The pharma giant’s…
MMedication Read More Takeaways on turmoil surrounding FDA fast-track drug programJanuary 18, 2026 WASHINGTON (AP) — A plan to slash drug review times at the Food and Drug Administration is sparking…
MMedication Read More FDA commissioner’s drug review plan sparks alarmJanuary 17, 2026 WASHINGTON (AP) — The Food and Drug Administration commissioner’s effort to drastically shorten the review of drugs favored…
HHealthcare Read More Which Is the Better Stock Buy?January 16, 2026 Eli Lilly leads the weight loss market ahead of Novo Nordisk. Eli Lilly also has a more diversified…
MMedication Read More Eli Lilly’s Most Promising Weight Loss Drug May Come With a Surprising Benefit: Pain ReliefJanuary 16, 2026 Retatrutide’s recent trial results suggest it may be even better than Eli Lilly’s already approved GLP-1 medication, tirzepatide.…